Abstract
In the present work, an attempt was made to develop and evaluate composite microspheres for controlled release of an anti-diabetic drug, nateglinide (NTG). The composite microspheres were prepared using rosin gum and ethyl cellulose as retardant polymers for drug release by solvent evaporation method. DSC and XRD analysis indicated the uniform dispersion of drug in the microspheres. The microspheres were capable of releasing drug for 24 h and the drug release mechanism followed non-Fickian transport. In vivo anti-diabetic activity conducted on wistar rats indicated that the plain (unformulated) NTG showed maximum percent reduction in blood glucose up to 2 h and then the blood glucose was increased. While in case of rats treated with test microspheres (RN6), the percent reduction in glucose level was slow up to 2 h as compared to plain drug, then it was gradually increased to 72.83 % at the end of 24 h. Histopathology of rat pancreas suggested that the regeneration of β cells was seen in the rats treated with RN6 microspheres. It can be concluded from the study that, the prepared microspheres are versatile delivery systems for nateglinide, which could release drug for longer period of time.
Keywords: Controlled release, ethyl cellulose, microspheres, nateglinide, rosin gum.
Drug Delivery Letters
Title:Composite Microspheres of Rosin Gum and Ethyl cellulose for Controlled Release of an Anti-diabetic Drug: in-vitro and in-vivo Assessment
Volume: 4 Issue: 3
Author(s): Kumari Niharika, Hanakunti M. Nanjappaiah, Akram A. Naikawadi and Raghavendra V. Kulkarni
Affiliation:
Keywords: Controlled release, ethyl cellulose, microspheres, nateglinide, rosin gum.
Abstract: In the present work, an attempt was made to develop and evaluate composite microspheres for controlled release of an anti-diabetic drug, nateglinide (NTG). The composite microspheres were prepared using rosin gum and ethyl cellulose as retardant polymers for drug release by solvent evaporation method. DSC and XRD analysis indicated the uniform dispersion of drug in the microspheres. The microspheres were capable of releasing drug for 24 h and the drug release mechanism followed non-Fickian transport. In vivo anti-diabetic activity conducted on wistar rats indicated that the plain (unformulated) NTG showed maximum percent reduction in blood glucose up to 2 h and then the blood glucose was increased. While in case of rats treated with test microspheres (RN6), the percent reduction in glucose level was slow up to 2 h as compared to plain drug, then it was gradually increased to 72.83 % at the end of 24 h. Histopathology of rat pancreas suggested that the regeneration of β cells was seen in the rats treated with RN6 microspheres. It can be concluded from the study that, the prepared microspheres are versatile delivery systems for nateglinide, which could release drug for longer period of time.
Export Options
About this article
Cite this article as:
Niharika Kumari, M. Nanjappaiah Hanakunti, A. Naikawadi Akram and V. Kulkarni Raghavendra, Composite Microspheres of Rosin Gum and Ethyl cellulose for Controlled Release of an Anti-diabetic Drug: in-vitro and in-vivo Assessment, Drug Delivery Letters 2014; 4 (3) . https://dx.doi.org/10.2174/2210303104666140909004015
DOI https://dx.doi.org/10.2174/2210303104666140909004015 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardioprotective Effects of Sour Cherry Seed Extract (SCSE) on the Hypercholesterolemic Rabbit Heart
Current Pharmaceutical Design Targeting Nrf2 in Protection Against Renal Disease
Current Medicinal Chemistry Role of Connexins and Pannexins in Ischemic Stroke
Current Medicinal Chemistry Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?
CNS & Neurological Disorders - Drug Targets Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design Complement 3 Receptor Expression in Individuals with Type 2 Diabetes
Recent Patents on Anti-Infective Drug Discovery Retinoids: Impact on Adiposity, Lipids and Lipoprotein Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Design, Synthesis and Biological Evaluation of Antipicornaviral Pyrrole-Containing Peptidomimetics
Protein & Peptide Letters How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets Early-life Programming of Type 2 Diabetes Mellitus: Understanding the Association between Epigenetics/Genetics and Environmental Factors
Current Genomics Endothelin-1 and Human Platelets
Current Vascular Pharmacology Pathogenesis and Clinical Features of Obesity and Insulin Resistance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology Review of Diabetic Polyneuropathy: Pathogenesis, Diagnosis and Management According to the Consensus of Egyptian Experts
Current Diabetes Reviews Editorial [Hot topic: NKT Cell Therapy (Guest Editor: Masashi Emoto)]
Current Immunology Reviews (Discontinued) Bioactive Compounds in Diabetic Cardiomyopathy: Current Approaches and Potential Diagnostic and Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondrial Uncoupling and the Regulation of Glucose Homeostasis
Current Diabetes Reviews Role of Free Fatty Acid Receptor 2 (FFAR2) in the Regulation of Metabolic Homeostasis
Current Drug Targets Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry